BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 34446352)

  • 1. Incidence of acute kidney injury after teicoplanin- or vancomycin- and piperacillin/tazobactam combination therapy: A comparative study using propensity score matching analysis.
    Sazanami K; Inose R; Yagi T; Dote S; Horiuchi N; Kobayashi Y; Muraki Y
    J Infect Chemother; 2021 Dec; 27(12):1723-1728. PubMed ID: 34446352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk Factors for Teicoplanin-Associated Acute Kidney Injury in Patients with Hematological Malignancies: Focusing on Concomitant Use of Tazobactam/Piperacillin.
    Morinaga Y; Tanaka R; Tatsuta R; Takano K; Hashimoto T; Ogata M; Hiramatsu K; Itoh H
    Biol Pharm Bull; 2024; 47(5):988-996. PubMed ID: 38763761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lowered Risk of Nephrotoxicity through Intervention against the Combined Use of Vancomycin and Tazobactam/Piperacillin: A Retrospective Cohort Study.
    Oda K; Hashiguchi Y; Katanoda T; Nakata H; Jono H; Saito H
    Microbiol Spectr; 2021 Sep; 9(1):e0035521. PubMed ID: 34346742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for acute kidney injury in vancomycin and piperacillin/tazobactam combination therapy: A retrospective study.
    Yamashita Y; Kawaguchi H; Yano T; Sakurai N; Shibata W; Oshima K; Imai T; Yamada K; Nakamura Y; Nagayama K; Kakeya H
    J Infect Chemother; 2021 Nov; 27(11):1614-1620. PubMed ID: 34366231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nephrotoxicity of teicoplanin-based combination therapy: focus on piperacillin/tazobactam and other anti-pseudomonal β-lactams.
    Tai CH; Shao CH; Wang CC; Lin FJ; Wang JT; Wu CC
    J Antimicrob Chemother; 2021 Jan; 76(2):499-506. PubMed ID: 33152760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam or Cefepime: A Retrospective Cohort Study.
    Hammond DA; Smith MN; Painter JT; Meena NK; Lusardi K
    Pharmacotherapy; 2016 May; 36(5):463-71. PubMed ID: 26952639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vancomycin with concomitant piperacillin/tazobactam vs. cefepime or meropenem associated acute kidney injury in the critically ill: A multicenter propensity score-matched study.
    Buckley MS; Komerdelj IA; D'Alessio PA; Rangan P; Agarwal SK; Tinta NC; Martinez BK; Ziadat DS; Yerondopoulos MJ; Kobic E; Kane-Gill SL
    J Crit Care; 2022 Feb; 67():134-140. PubMed ID: 34768175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of serum concentration and concomitant drugs on vancomycin-induced acute kidney injury in haematologic patients: a single-centre retrospective study.
    Okada N; Chuma M; Azuma M; Nakamura S; Miki H; Hamano H; Goda M; Takechi K; Zamami Y; Abe M; Ishizawa K
    Eur J Clin Pharmacol; 2019 Dec; 75(12):1695-1704. PubMed ID: 31511938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher incidence of acute kidney injury in patients treated with piperacillin/tazobactam than in patients treated with cefepime: a single-center retrospective cohort study.
    Kadomura S; Takekuma Y; Sato Y; Sumi M; Kawamoto K; Itoh T; Sugawara M
    J Pharm Health Care Sci; 2019; 5():13. PubMed ID: 31210955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin-Tazobactam Compared to Those on Vancomycin and Cefepime.
    Navalkele B; Pogue JM; Karino S; Nishan B; Salim M; Solanki S; Pervaiz A; Tashtoush N; Shaikh H; Koppula S; Koons J; Hussain T; Perry W; Evans R; Martin ET; Mynatt RP; Murray KP; Rybak MJ; Kaye KS
    Clin Infect Dis; 2017 Jan; 64(2):116-123. PubMed ID: 27986669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephrotoxicity of concomitant piperacillin/tazobactam and teicoplanin compared with monotherapy.
    Workum JD; Kramers C; Kolwijck E; Schouten JA; de Wildt SN; Brüggemann RJ
    J Antimicrob Chemother; 2021 Jan; 76(1):212-219. PubMed ID: 32944771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of teicoplanin versus vancomycin in combination with piperacillin-tazobactam or meropenem for the risk of acute kidney injury.
    Aslan AT; Pashayev T; Dağ O; Akova M
    Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):1953-1961. PubMed ID: 33884515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime.
    Gomes DM; Smotherman C; Birch A; Dupree L; Della Vecchia BJ; Kraemer DF; Jankowski CA
    Pharmacotherapy; 2014 Jul; 34(7):662-9. PubMed ID: 24753221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of Acute Kidney Injury in Patient Receiving Piperacillin - Tazobactam: A Hospital-based Study from Qatar.
    Khan FY; Abdalhadi AM; Kazman R; Mudawi DS; Shariff K; Suliman A; Chaudhry HS; Sharma R; Elballat A; Yousif AB; Alshurafa A; Ata F
    Acta Med Indones; 2021 Apr; 53(2):156-163. PubMed ID: 34251343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin/Tazobactam Treatment Among Hospitalized Children.
    Downes KJ; Cowden C; Laskin BL; Huang YS; Gong W; Bryan M; Fisher BT; Goldstein SL; Zaoutis TE
    JAMA Pediatr; 2017 Dec; 171(12):e173219. PubMed ID: 28973124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant vancomycin and piperacillin/tazobactam treatment is associated with an increased risk of acute kidney injury in Japanese patients.
    Haruki Y; Hagiya H; Haruki M; Inoue Y; Sugiyama T
    J Infect Chemother; 2020 Oct; 26(10):1026-1032. PubMed ID: 32561128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative incidence and excess risk of acute kidney injury in hospitalised patients receiving vancomycin and piperacillin/tazobactam in combination or as monotherapy.
    Carreno J; Smiraglia T; Hunter C; Tobin E; Lomaestro B
    Int J Antimicrob Agents; 2018 Nov; 52(5):643-650. PubMed ID: 30103003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Risk of Acute Kidney Injury in Patients Treated with Vancomycin and Piperacillin/Tazobactam Compared to Vancomycin and Meropenem or Doripenem: A Retrospective Cohort Study].
    Ide N; Sato S; Sawaguchi K
    Yakugaku Zasshi; 2019; 139(12):1609-1614. PubMed ID: 31787651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology of Acute Kidney Injury among Patients Receiving Concomitant Vancomycin and Piperacillin-Tazobactam: Opportunities for Antimicrobial Stewardship.
    Karino S; Kaye KS; Navalkele B; Nishan B; Salim M; Solanki S; Pervaiz A; Tashtoush N; Shaikh H; Koppula S; Martin ET; Mynatt RP; Murray KP; Rybak MJ; Pogue JM
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3743-50. PubMed ID: 27067325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerance and microbiological efficacy of cefepime or piperacillin/tazobactam in combination with vancomycin as empirical antimicrobial therapy of prosthetic joint infection: a propensity-matched cohort study.
    Triffault-Fillit C; Mabrut E; Corbin K; Braun E; Becker A; Goutelle S; Chaudier P; Fessy MH; Dupieux C; Laurent F; Gunst S; Lustig S; Chidiac C; Ferry T; Valour F
    J Antimicrob Chemother; 2020 Aug; 75(8):2299-2306. PubMed ID: 32407512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.